Xenter Raises $58.25 Million in Series B Financing
Health technology company Xenter has closed its Series B financing round, raising $58.25 million. The funds are intended to accelerate the commercial launch of the company's TechMed™ platform.
Draper, Utah – Health technology firm Xenter announced the successful closing of its Series B financing round on June 30, raising a total of $58.25 million. The company plans to use the capital to accelerate the commercial launch of its TechMed™ platform, further develop its wireless medical devices, and advance its AI-enabled Physical Intelligence™ technology.
The funding round saw participation from existing shareholders, family offices, and healthcare investors. Xenter aims to transform how healthcare data is captured, connected, and utilized within hospitals and physician offices.
The proceeds will also support expanded manufacturing of Xenter's technologies, along with clinical and regulatory initiatives. The company is preparing for the initial commercial launch of its diagnostics unit and plans clinical testing of its Guru™ physiological sensor in Transcatheter Aortic Valve Replacement (TAVR) procedures.
Xenter has also appointed Linda Vega to its Board of Directors. Vega brings decades of executive experience in banking, finance, corporate governance, and strategic capital planning, expected to bolster the company's strategic direction during its expansion phase.